Podcasts about CGH

Bài Giảng: Lấy Thập Tự Giá Làm Trung TâmDiễn giả: Derek PrinceChuyển ngữ: Đội ngũ Ba-rúcGhé thăm trang web: www.derekprince.com/vi để tiếp cận thêm nhiều dạy dỗ Kinh thánh tiếng Việt miễn phí của Derek Prince.Kênh Youtube:    / @mucvuderekprincevietnam  Bài giảng được dịch và lồng tiếng với sự cho phép của Derek Prince Ministry-------------------------------------Derek Prince (14/08/1915 24/09/2003) là một giáo sư giảng dạy Kinh Thánh quốc tế, ông rất được kính trọng vì những hiểu biết sâu sắc về thần học và đức tin Cơ Đốc chân chính của mình. Đức tin kiên định và sự tận tâm của ông trong việc nghiên cứu Kinh Thánh đã khiến ông trở thành một trong những giáo sư Kinh Thánh được kính trọng và ngưỡng mộ nhất trong thời đại mình.Ông là tác giả của hơn 100 cuốn sách và một kho tài nguyên giảng dạy Kinh Thánh vô giá khiến cho công việc và niềm đam mê của cuộc đời ông vẫn còn mãi. Được dịch sang hơn 100 ngôn ngữ, chúng là nguồn cho sự truyền cảm hứng và nguồn nghiên cứu cho hàng triệu Cơ Đốc Nhân trên toàn thế giới.-------------------------------------Anh chị em có thể nghe bài giảng audio của Giảng Luận Kinh Thánh tại địa chỉ sau:Spotify: https://sum.vn/HybEqApple podcast: https://sum.vn/SccJBGiảng Luận Kinh Thánh là dự án dịch thuật/lồng tiếng sang tiếng Việt các bài giảng, thông điệp Cơ Đốc kinh điển của những diễn giả đã được thời gian khẳng định và cộng đồng Cơ đốc chung xác nhận. Đây là dự án phi lợi nhuận nhằm cung cấp nguồn tư liệu cho các tôi tớ cùng con dân Chúa tham khảo và sử dụng miễn phí. Để hiểu hơn về chúng tôi vui lòng truy cập website :https://giangluankinhthanh.net/Đội ngũ Giảng Luận Kinh Thánh hoan nghênh mọi đề nghị cộng tác của quý con cái Chúa khắp nơi trong các lĩnh vực như dịch thuật, lồng tiếng, quảng bá, cầu thay, v.v. Nếu quý con cái Chúa sẵn lòng đóng góp công sức của mình vào bất cứ lĩnh vực nào, cùng đồng công trong những sứ điệp giúp tỉnh thức nhiều người.Xin vui lòng điền thông tin cá nhân vào biểu mẫu sau: Kênh Giảng Luận Kinh Thánh hoạt động vì các mục tiêu phi lợi nhuận, không phát quảng cáo. Vì vậy, chúng tôi mong tiếp tục nhận được sự dâng hiến và ủng hộ của quý con cái Chúa khắp nơi trong việc phát triển kênh. Quý vị có thể dâng hiến theo thông tin trong biểu mẫu sau: https://sum.vn/ZZ19mXin chân thành cảm ơn!#Giangluankinhthanh #derekprince #thaptugia #baigiangkinhthanh #baigiangcodoc #hockinhthanh #loiChua

Bài Giảng: Lấy Thập Tự Giá Làm Trung TâmDiễn giả: Derek PrinceChuyển ngữ: Đội ngũ Ba-rúcGhé thăm trang web: www.derekprince.com/vi để tiếp cận thêm nhiều dạy dỗ Kinh thánh tiếng Việt miễn phí của Derek Prince.Kênh Youtube:    / @mucvuderekprincevietnam  Bài giảng được dịch và lồng tiếng với sự cho phép của Derek Prince Ministry-------------------------------------Derek Prince (14/08/1915 24/09/2003) là một giáo sư giảng dạy Kinh Thánh quốc tế, ông rất được kính trọng vì những hiểu biết sâu sắc về thần học và đức tin Cơ Đốc chân chính của mình. Đức tin kiên định và sự tận tâm của ông trong việc nghiên cứu Kinh Thánh đã khiến ông trở thành một trong những giáo sư Kinh Thánh được kính trọng và ngưỡng mộ nhất trong thời đại mình.Ông là tác giả của hơn 100 cuốn sách và một kho tài nguyên giảng dạy Kinh Thánh vô giá khiến cho công việc và niềm đam mê của cuộc đời ông vẫn còn mãi. Được dịch sang hơn 100 ngôn ngữ, chúng là nguồn cho sự truyền cảm hứng và nguồn nghiên cứu cho hàng triệu Cơ Đốc Nhân trên toàn thế giới.-------------------------------------Anh chị em có thể nghe bài giảng audio của Giảng Luận Kinh Thánh tại địa chỉ sau:Spotify: https://sum.vn/HybEqApple podcast: https://sum.vn/SccJBGiảng Luận Kinh Thánh là dự án dịch thuật/lồng tiếng sang tiếng Việt các bài giảng, thông điệp Cơ Đốc kinh điển của những diễn giả đã được thời gian khẳng định và cộng đồng Cơ đốc chung xác nhận. Đây là dự án phi lợi nhuận nhằm cung cấp nguồn tư liệu cho các tôi tớ cùng con dân Chúa tham khảo và sử dụng miễn phí. Để hiểu hơn về chúng tôi vui lòng truy cập website :https://giangluankinhthanh.net/Đội ngũ Giảng Luận Kinh Thánh hoan nghênh mọi đề nghị cộng tác của quý con cái Chúa khắp nơi trong các lĩnh vực như dịch thuật, lồng tiếng, quảng bá, cầu thay, v.v. Nếu quý con cái Chúa sẵn lòng đóng góp công sức của mình vào bất cứ lĩnh vực nào, cùng đồng công trong những sứ điệp giúp tỉnh thức nhiều người.Xin vui lòng điền thông tin cá nhân vào biểu mẫu sau: Kênh Giảng Luận Kinh Thánh hoạt động vì các mục tiêu phi lợi nhuận, không phát quảng cáo. Vì vậy, chúng tôi mong tiếp tục nhận được sự dâng hiến và ủng hộ của quý con cái Chúa khắp nơi trong việc phát triển kênh. Quý vị có thể dâng hiến theo thông tin trong biểu mẫu sau: https://sum.vn/ZZ19mXin chân thành cảm ơn!#Giangluankinhthanh #derekprince #thaptugia #baigiangkinhthanh #baigiangcodoc #hockinhthanh #loiChua

Bài Giảng: Lấy Thập Tự Giá Làm Trung TâmDiễn giả: Derek PrinceChuyển ngữ: Đội ngũ Ba-rúcGhé thăm trang web: www.derekprince.com/vi để tiếp cận thêm nhiều dạy dỗ Kinh thánh tiếng Việt miễn phí của Derek Prince.Kênh Youtube:    / @mucvuderekprincevietnam  Bài giảng được dịch và lồng tiếng dưới cho phép của Derek Prince-------------------------------------Derek Prince (14/08/1915 24/09/2003) là một giáo sư giảng dạy Kinh Thánh quốc tế, ông rất được kính trọng vì những hiểu biết sâu sắc về thần học và đức tin Cơ Đốc chân chính của mình. Đức tin kiên định và sự tận tâm của ông trong việc nghiên cứu Kinh Thánh đã khiến ông trở thành một trong những giáo sư Kinh Thánh được kính trọng và ngưỡng mộ nhất trong thời đại mình.Ông là tác giả của hơn 100 cuốn sách và một kho tài nguyên giảng dạy Kinh Thánh vô giá khiến cho công việc và niềm đam mê của cuộc đời ông vẫn còn mãi. Được dịch sang hơn 100 ngôn ngữ, chúng là nguồn cho sự truyền cảm hứng và nguồn nghiên cứu cho hàng triệu Cơ Đốc Nhân trên toàn thế giới.-------------------------------------Anh chị em có thể nghe bài giảng audio của Giảng Luận Kinh Thánh tại địa chỉ sau:Spotify: https://sum.vn/HybEqApple podcast: https://sum.vn/SccJBGiảng Luận Kinh Thánh là dự án dịch thuật/lồng tiếng sang tiếng Việt các bài giảng, thông điệp Cơ Đốc kinh điển của những diễn giả đã được thời gian khẳng định và cộng đồng Cơ đốc chung xác nhận. Đây là dự án phi lợi nhuận nhằm cung cấp nguồn tư liệu cho các tôi tớ cùng con dân Chúa tham khảo và sử dụng miễn phí. Để hiểu hơn về chúng tôi vui lòng truy cập website :https://giangluankinhthanh.net/Đội ngũ Giảng Luận Kinh Thánh hoan nghênh mọi đề nghị cộng tác của quý con cái Chúa khắp nơi trong các lĩnh vực như dịch thuật, lồng tiếng, quảng bá, cầu thay, v.v. Nếu quý con cái Chúa sẵn lòng đóng góp công sức của mình vào bất cứ lĩnh vực nào, cùng đồng công trong những sứ điệp giúp tỉnh thức nhiều người.Xin vui lòng điền thông tin cá nhân vào biểu mẫu sau: Kênh Giảng Luận Kinh Thánh hoạt động vì các mục tiêu phi lợi nhuận, không phát quảng cáo. Vì vậy, chúng tôi mong tiếp tục nhận được sự dâng hiến và ủng hộ của quý con cái Chúa khắp nơi trong việc phát triển kênh. Quý vị có thể dâng hiến theo thông tin trong biểu mẫu sau: https://sum.vn/ZZ19mXin chân thành cảm ơn!#Giangluankinhthanh #derekprince #thaptugia #baigiangkinhthanh #baigiangcodoc #hockinhthanh #loiChua

Bài Giảng: Lấy Thập Tự Giá Làm Trung TâmDiễn giả: Derek PrinceChuyển ngữ: Đội ngũ Ba-rúcGhé thăm trang web: www.derekprince.com/vi để tiếp cận thêm nhiều dạy dỗ Kinh thánh tiếng Việt miễn phí của Derek Prince.Kênh Youtube:    / @mucvuderekprincevietnam  Bài giảng được dịch và lồng tiếng dưới cho phép của Derek Prince-------------------------------------Derek Prince (14/08/1915 24/09/2003) là một giáo sư giảng dạy Kinh Thánh quốc tế, ông rất được kính trọng vì những hiểu biết sâu sắc về thần học và đức tin Cơ Đốc chân chính của mình. Đức tin kiên định và sự tận tâm của ông trong việc nghiên cứu Kinh Thánh đã khiến ông trở thành một trong những giáo sư Kinh Thánh được kính trọng và ngưỡng mộ nhất trong thời đại mình.Ông là tác giả của hơn 100 cuốn sách và một kho tài nguyên giảng dạy Kinh Thánh vô giá khiến cho công việc và niềm đam mê của cuộc đời ông vẫn còn mãi. Được dịch sang hơn 100 ngôn ngữ, chúng là nguồn cho sự truyền cảm hứng và nguồn nghiên cứu cho hàng triệu Cơ Đốc Nhân trên toàn thế giới.-------------------------------------Anh chị em có thể nghe bài giảng audio của Giảng Luận Kinh Thánh tại địa chỉ sau:Spotify: https://sum.vn/HybEqApple podcast: https://sum.vn/SccJBGiảng Luận Kinh Thánh là dự án dịch thuật/lồng tiếng sang tiếng Việt các bài giảng, thông điệp Cơ Đốc kinh điển của những diễn giả đã được thời gian khẳng định và cộng đồng Cơ đốc chung xác nhận. Đây là dự án phi lợi nhuận nhằm cung cấp nguồn tư liệu cho các tôi tớ cùng con dân Chúa tham khảo và sử dụng miễn phí. Để hiểu hơn về chúng tôi vui lòng truy cập website :https://giangluankinhthanh.net/Đội ngũ Giảng Luận Kinh Thánh hoan nghênh mọi đề nghị cộng tác của quý con cái Chúa khắp nơi trong các lĩnh vực như dịch thuật, lồng tiếng, quảng bá, cầu thay, v.v. Nếu quý con cái Chúa sẵn lòng đóng góp công sức của mình vào bất cứ lĩnh vực nào, cùng đồng công trong những sứ điệp giúp tỉnh thức nhiều người.Xin vui lòng điền thông tin cá nhân vào biểu mẫu sau: Kênh Giảng Luận Kinh Thánh hoạt động vì các mục tiêu phi lợi nhuận, không phát quảng cáo. Vì vậy, chúng tôi mong tiếp tục nhận được sự dâng hiến và ủng hộ của quý con cái Chúa khắp nơi trong việc phát triển kênh. Quý vị có thể dâng hiến theo thông tin trong biểu mẫu sau: https://sum.vn/ZZ19mXin chân thành cảm ơn!#Giangluankinhthanh #derekprince #thaptugia #baigiangkinhthanh #baigiangcodoc #hockinhthanh #loiChua

In this episode, Tony speaks with Bonface G and Ian O about Trump; Musk's Twitter buyout + Facebook vs Twitter UI + censorship; homelessness; American philanthropy; the hustler movement + the hustler narrative + the populism of His Excellency President and Doctor William Samoei Ruto, CGH, EGH, EBS; Kenyatta II + milk monopoly; great movie & TV villains; consequences and comeuppance in cinema; Dave chappelle + abortion; and many other topics.  -SPOILER WARNING for Tenet (2020); Sex/Life; The Wire; Breaking Bad; Westworld; Game of Thrones; Dune: Part One (2021); The Handmaid's Tale; High Maintenance; Lost in Translation (2003); etc.  -Recorded April 2022  -Get first access to audio on Spotify, Google Podcasts, and Apple Podcasts. And feel free to drop us a line on X/Instagram @televishenipod or by email at thetelevishenipodcast@gmail.com

Tonight, we talk about The Coast Guard House, a great New England restaurant and landmark. Bob Leonard, Co-owner, and Elisa Wybraniec, Wine Director, talk about the great food, wine menu, and the large variety CGH offers. We listen to music about the sea to set the mood. For more information, you can call (401) 789-0700 or go to www.TheCoastGuardHouse.com 

Ethical considerations are essential in genomic medicine and clinical practice. In this episode, our guests dive into the details of ethical principles, highlighting how they can be brought into practice in the clinic, whilst considering the experiences and feelings of patients and participants. Our host, Dr Natalie Banner, Director of Ethics at Genomics England, speaks to Professor Sir Jonathan Montgomery and Dr Latha Chandramouli. Jonathan is the Chair of the Genomics England Ethics Advisory Committee, and a Professor of Health Care Law at University College London. Latha is a member of the Ethics Advisory Committee and the Participant Panel at Genomics England, and is a Consultant Community Paediatrician working with children with complex needs.   "You asked why ethics is important and how it operates, I suppose the main thing for me is that these are tricky questions, and you need all the voices, all the perspectives, all the experience in the room working through at the same time. You don't want to have separate discussions of things."   You can read the transcript below or download it here: https://files.genomicsengland.co.uk/documents/Podcast-transcripts/Why-are-ethical-considerations-crucial-in-genomics-research-and-clinical-practice.docx Natalie: Welcome to Behind the Genes.   Jonathan: The first difference is that the model we've traditionally had around clinical ethics, which sort of assumes all focus is around the patient individually, is not enough to deal with the challenges that we have, because we also have to understand how we support families to take decisions. Families differ enormously, some families are united, some families have very different needs amongst them, and we have to recognise that our ethical approaches to  genomic issues must respect everybody in that.  Natalie: My name is Natalie Banner and I'm the Director of Ethics here at Genomics England. On today's episode, I'm joined by Chair of our Ethics Advisory Committee, Professor Sir Jonathan Montgomery and Dr Latha Chandramouli, member of the Ethics Advisory Committee and the Participant Panel, who's also a community paediatrician working with children with complex needs.  Today we'll be discussing why ethical considerations are crucial in genomics research and clinical practice and what consent means in the context of genomics. If you enjoy today's episode, we'd love your support. Please like, share and rate us wherever you listen to your podcasts.  At Genomics England, we have an Ethics Advisory Committee, which exists to promote a strong ethical foundation for all of our programmes, our processes, and our partnerships. This can mean things like acting as a critical friend, an external group of experts to consult. It can mean ensuring Genomics England is being reflective and responsive to emerging ethical questions, especially those that arise as we work with this really complex technology of genomics that sits right at the intersection of clinical care and advancing research. And it can also ensure that we are bringing participant voices to the fore in all of the work that we're doing.   I'm really delighted today to welcome two of our esteemed members of the ethics advisory committee to the podcast. Professor Sir Jonathan Montgomery, our Chair, and Dr Latha Chandramouli, member of our Participant Panel. So, Jonathan, if I could start with you, could you tell us a little bit about your background and what you see as the role of the ethics advisory committee for us at Genomics England?  Jonathan: Thanks very much, Natalie. My background professionally is I'm an academic, I'm a professor at University College London, and I profess healthcare law the subject that I've sort of had technical skills in. But I've also spent many years involved in the governance of the National Health Service, so I currently chair the board of the Oxford University Hospital's NHS Foundation Trust.   I've spent quite a lot of time on bodies trying to take sensible decisions on behalf of the public around difficult ethical issues. The most relevant one to Genomics England is I chaired the Human Genetics Commission for three years which was a really interesting group of people from many backgrounds. The commission itself primarily combined academics in ethics, law and in clinical areas, and there was a separate panel of citizens think grappling with things that are really important. Genomics England has a bit of that pattern, but it's really important that the ethics advisory committee brings people together to do that. You asked why ethics is important and how it operates, I suppose the main thing for me is that these are tricky questions, and you need all the voices, all the perspectives, all the experience in the room working through at the same time. You don't want to have separate discussions of things. My aim as Chair of the advisory committee is essentially to try and reassure myself that we've heard all the things that we need to hear and we've had a chance to discuss with each other as equals what it is that that leads us to think, and then to think about how to advise within Genomics England or other people on what we've learnt from those processes.  Natalie: Fantastic. Thank you, Jonathan. And as you mentioned, the necessity of multiple different perspectives, this brings me to Latha. You have lots of different hats that you bring to the Ethics Advisory Committee, could you tell us a little bit about those?  Latha: Thank you, Natalie, for that introduction. I'm Latha Chandramouli, I'm a Consultant Community Paediatrician and I'm based in Bristol employed by Siron Care & Health. I'm a parent of twins and from my personal journey, which is how I got involved, my twins are now 21 so doing alright, we had a very, very stormy difficult time when they were growing up with our daughter having epilepsy, which just seemed to happen quite out of the blue sometimes. It started to increase in frequency the year of GCSE, to the point that she would just fall anywhere with no warnings and hurt herself. This was difficult for me because as a clinician, I was also treating patients with epilepsy. I also was looking at the journeys of other people and was able to resonate with the anxiety as a parent. Worry about sudden death in epilepsy, for example, at night, these were the kind of difficult conversations I was having with parents, and I was now on the other side of the consultation table.  I was also doing neurology in those jobs in a unit where there was epilepsy surgery happening, so it was, in very simple terms, very close to home. It was quite hard to process, but equally my job I felt was I should not separate myself as a parent but also as a clinician because I had information, I had knowledge, and we had conversations with my daughter's clinician.   We were then recruited into the 100,000 Genomes Project which had just started, so we were just a year after it had started. That was an interesting experience. We were in a tertiary centre with a lovely clinical geneticist team, we had the metabolic team, we had loads of teams involved in our daughter's care. We could understand as a clinician, but there was also my husband, although a clinician, not into paediatrics and was in a different field. It was important that it was the whole family getting recruited into the journey. My daughter also was quite young, so obviously we have parenting responsibility, but we were very keen to make sure they knew exactly what they were getting into in terms of the long-term issues. Despite being informed, at times there were things that we went in with without understanding the full implications because life happens in that odyssey.   I think that was my biggest learning from those exercises when I began to question certain other things because I then had a breast cancer journey, but obviously I was not recruited as part of that process for the 100k. Those were kind of some of the questions coming in my head, how does the dynamic information sharing happen, and that's how I got involved, found out a bit more about the participant panel, and that's how I got involved from 2018 which has been an interesting experience.   Firstly, I think with Genomics England they are probably one of the groups of organisations having a big panel of people, genuinely interested in wanting to make a difference and represent thousands of participants who have got their data saved in the research library, recruited under the two broad arms of cancer and rare disease. We were under the rare disease arm, although I could resonate with the cancer arm because of my own experience.  At various times there were lots of opportunities to think about how data is accessed, are we getting more diverse access to data, all those different issues. At various points we have been involved in asking those questions. We all have different skillsets, you see, in our group. Some have got information governance hats; some have got data hats and PR hats. I've got a clinical hat and a clinical educator hat. I am a paediatrician, so I have recruited people for the same, for the DDD, for CGH etc, and I've always gone through the principles of consenting, confidentiality, the ethics. I also work in a field, Natalie, where there is a huge, as you are aware with the NHS resource issues, there's huge gaps and waiting lists, so it's trying to make sense of what is the best thing to do for that patient or that family at that point in life. Are we obsessed by a diagnostic label? Are we going down a needs-based approach? It's having always those pragmatic decisions to be made. That's one of my clinical hats.  I also am an educator so I'm very keen that young medical students, be it nursing students, everybody understands genomics and they're signing up to it so that we can mainstream genomics. Those are some of my alternative hats which kind of kick in a bit.  Natalie: Fantastic, thank you, Latha. As you say, there are so many different perspectives there. You talk about kind of the role of the whole family as part of the journey. You talked about consent, confidentiality, data access issues, lots of questions of uncertainty. Perhaps, Jonathan, I can come to you first to talk a little bit about what is it about the ethical issues in genomics that may feel a little different. Are they unique or are they the same sorts of ethical issues that come across in other areas of clinical practice and research? Is there something particularly challenging in the area of genomics from an ethical perspective? Jonathan: Thanks, Natalie. I think all interesting ethical issues are challenging, but they're challenging in different ways. I'm always nervous about saying that it's unique to genomics because there are overlaps with other areas. But I do think there are some distinctive features about the challenges in genomics and I suppose I would say they probably fall in three groups of things that we should think about. The first you've touched on which is that information about our genomics is important not just for the individual person where you generate that data but it's important for their families as well. I think the first difference is that the model we've traditionally had around clinical ethics, which sort of assumes it all focuses around the patient individual, is not enough to deal with the challenges that we have, because we also have to understand how we support families to take decisions and families differ enormously. Some families are united, some families have very different needs amongst them, and we have to recognise that our ethical approach is genomic issues must respect everybody in that, so I think that's the first difference.  I think the second difference is that the type of uncertainty involved in genomics extends much further than many other areas. We're talking about the impact on people's whole lives and it's not like a decision about a particular medication for a problem we have now or an operation. We're having to help people think about the impact it has on their sense of identity, on things that are going to happen sometime in the future.   And then thirdly, I think the level of uncertainty is different in genomics from other areas of medicine, and the particular thing I think is different that we have to work out how to address is that we can't really explain now all the things that are going to happen in the future, because we don't know. But we do know that as we research the area, we're going to find out more. So, what are our obligations to go back to people and say, “we worked with you before and you helped us out giving data into the studies. We couldn't tell you anything then that would be useful to you, but actually we can now.”. Now, that's different. That continuity sometimes talked about, you know, what are our obligations to recontact people after a study. You don't usually have those in the ethical areas we're familiar with; you're usually able to deal with things in a much more focused way.   I think those differences, that it's not just the individual, it's the family, that it's not just about a specific intervention but it's about an impact on people's lives and that we will need to think about what we had to do in the future as well as what we do immediately. They make it different in genomics. Some areas of healthcare have those as well, but I'm not aware of anywhere that has all of that in the same position.  Natalie: Latha, I'm wondering if that kind of resonates with your experience, particularly the navigating of uncertainty over time?  Latha: Yes. I would say that's exactly what you've said, Jonathan. I think it's the whole process of consenting with the view that you do not know much more beyond what you know about the situation here and now. Part of that is like any other situation, that's why we have evolved from I would say penicillin to the SMA gene therapy. If we did not do this, we wouldn't reach frontiers of medicine and kind of that's how I explained to families when I'm recruiting and I'm also very clear that it's not all about research but it's combination of the tool and focusing on your, but it's also helpful for research even if you do not get answers. I think it's very important at that stage, Natalie, that we have to be clear we may not get many answers at the very outset and also when do we really look at data, do we have that kind of realistic pragmatic resources to be able to relook every time? Is there a method of dynamically having that information from our NHS spine if somebody of the trio has contracted a condition, would that be fed in.   Those are the kind of questions parents and families ask. I cannot honestly answer that, and I often say that is optimal plan. If things go to plan, that will be the area we'd be heading towards, but currently I can't give you timelines. I think it's important we are honest at the outset and manage expectations. That's how you engage families and, in my case, it's more these children and families, so engaging is crucial. As you mentioned, it's also the question that gets asked is very simply in my mind, you know, sometimes there is that conflict because of my own personal recruitment to the 100k project, I have an interest in genomics and, therefore, I would be very keen to embark on that journey and I feel that is the way forward.   I also understand as a member of my clinical team, for example, where I know there's a huge waiting list, how am I best using the taxpayers' money that's been entrusted to us. If I think the waiting list is so high, can I see two further patients in that time that I'm using to consent which is not going to add much more to that child's journey, for example, with autism or ADHD. It's trying to be careful where is the ethics in doing an investigation, and that's like in any situation as a clinician. I think that's not much different, but it is kind of similar, but it opens up a huge area of uncertainty. As you would with any investigations, if you just went and did scans on everybody, you might pick things up which you don't need to do anything about. It's being sensible and being honest.  Jonathan: And for me, Latha, that raises two areas which I think are really interesting about genomics. The first of those is the language we've tended to use about consent I don't think captures all the ethical issues that we raise, because we've tended to think about consent of something that happens once and then gives people permission to do things. Whereas what you've described, and what we find ourselves often thinking about, is that we have to get a respectful relationship with people, so the consent is not to doing certain things, it's to agree to part of what I think about as a common enterprise. So, patients and families are partners with the clinicians and the researchers, and it's not that they sign a form and then the consent issue goes away, which is how lawyers tend to think about it, it's that we're starting something together and then we need to think about how do we keep the conversation going with mutual respect to make sure that everybody's values are there.   I think the second thing you picked up is a sense of the need for a better explanation of how research and care interact with each other. Because the care we get now is built on the evidence that people have contributed to in the past, so we're benefitting from our predecessors, and we want to contribute to our successors and our family getting better care in the future. I think one of the things about genomics is that the gap between those two things is really non-existent in genomics, whereas if you take a medicine, the research that's been done to make sure that medicine is safe and effective will have been done on a group of people some time in the past that I'll never meet, whereas in genomics I'm part of the production of that. I may get some benefit now, my friends or family may get some benefit, but there isn't this sort of separation between the care and the research bit that we're used to being able to think about. This is a much more mutual exercise and the stakes that we all have in it are therefore intertwined much more closely than they are in some areas of medicine.  Latha: I agree totally. In our case, for example, I went in in thinking we might get a targeted medication. I know there are certain levels of epilepsy medications anyway, so in principle it wouldn't have mattered a lot. However, it was important to know what the outcome was going to be because we had various labels, potential mitochondrial disease, potentially some susceptibility disorder, so we were on a spectrum from something very minimal to the other end on neurodegenerative situation. We were left dangling and we thought it would be good to embark on this journey, at least there'll be some outcome, some prognostic outcome, and more importantly we don't have any answers, but we actually can be a hopeful story for someone else in that same position, and I think that's how we've embarked on it. That's kind of my personal experience. But in just harking back to some of the ethical issues, it's again very clear educating the clinicians, as you said, it's that relationship; it's not just a piece of paper, it's that development of relationship with your families, some of whom have got very complex issues going on in their lives themselves. I work in a very, very deprived part of Bristol, which is the highest deprivation index, so they have got lots of intergenerational things going on, there is poverty, there is learning issues and crime, lots of things going on. You've got to time it right, what is important for this family here and now, and then work on it. There's also the other issue that we may not continue to remain their clinicians after recruiting. I think that's so important to recognise because the results might come back but you kind of discharge them and it may take a few years by the time the results come. How do you then cross that bridge if some unexpected results come, which then means contacting various other extended family members. I think that's the bit we all do because that's part of the journey we've embarked on, but it's also thinking is there someone else who's probably better placed, like a GP or a primary care person who's actually holding the entire family and not just one person, not just the adult who has been the index patient. It's just trying to think the ethics of it because it's all about engagement and being transparent with families.  Jonathan: I think you've put your finger on another element that's really important about the ethics. In the same way as in relation to the position of the individual patient, and we need to see them in families, which doesn't fit very easily with lots of the clinical ethics that we've been used to. It's also the case that a lot of the traditional clinical ethics has focused on the individual responsibilities of clinicians, whereas what you've just described is that we have to work out what the system's responsibilities are, because it may not be the same clinician who is enabling good ethical practice to be pursued. These are both ways in which our paradigm of ethics has to be expanded from other areas of medicine.  Latha: Yes, I agree. And the other bit I think we can probably reassure quite nicely is about the ethics about information governance and we as data custodians storing information, how do we give with great ethics and discussion the access to research and being mindful that it is again thinking along the same principles GMC kind of had about the good for the common good and using resources equitably, but again being sensible with equality issues that a single condition doesn't get forgotten. It's that right balance that whilst we are doing common good, we might have a condition which might have a treatable medication, but we have to focus on that as well as research. I think it's interwoven, all these ethical questions.  Jonathan: I completely agree, Latha. That interwoven bit is something where we need to be able to think through, “what is the role of Genomics England to improving that?”. I think we've got issues around the good stewardship of information which can't be left with an individual clinician, they can only do that effectively if the system supports them and their colleagues in doing that. But we've also got to be proactive, we've got to recognise the limitations of the system, so one of the really important initiatives from Genomics England is the Diverse Data initiative because we know that without aiming to solve the problem, we will get a skewed dataset and clinicians can't properly look after people. That tells us that the ethics in this area has to do more than avoid things going wrong, it also has to work out what it means to do things right, and what systems we have to put in place to do that. I think that's a particular example of a shift we need to do across our ethics around healthcare.   If speak to the sort of things that lawyers have got wrong around this in the past and some of our history, we focused a lot of our effort on stopping things going wrong. That has meant that we haven't spent as much time as we need to on thinking about how to make things go right, because stopping things going wrong is almost always too late. What we have to do if we're being proactive is work out how to set things up in a way that will make sure that the chances of it going wrong are quite small and the chances of doing good are much increased. I think that's one of the key challenges that we have in Genomics England and as an Ethics Advisory Committee. The things we've inherited tell us quite a lot about things that have gone wrong, but actually what we're trying to do is to get our heads around what could go right and how to make sure it does.  Latha: Also, you mentioned about Diverse Data, I think that's another important thing as we noticed in COVID as well. There were lots of disparities in the social model and the inequalities that have resulted in death, but also potentially HLA or epigenetic issues which could have contributed. We do have the COVID-19 genomic datasets, but it's again important to make sure that we don't perceive certain ethnic minority populations. Just not accessing or considering them to be hard to reach, I would say for them Genomics England is hard to reach. It's looking at it slightly differently and thinking, “how can we reach them? how do we maybe use community workers and maybe even clinicians?”, I think they've got the best trusting relationships with their clinicians and using them to recruit. As you say, even before things get more complicated, you recruit them earlier so that you'd go down the prevention route rather than the gone wrong route and then look for answers later.  Jonathan: Latha, I think you put your finger on something really challenging for a group like the Ethics Advisory Committee at Genomics England, which is that however hard we try to get a range of experiences and voices, that's not a substitute for getting out and hearing from people in real world situations. I think one of the things I've learnt over the years from my national health service work is that you cannot expect people to come to you, you need to go to them. In COVID when we were trying to understand why some groups were more reluctant to take up vaccines than others, there was no point in doing that sitting in your own places, you had to listen to people's concerns and understand why they were there. One of the things we're going to have to be able to do as the Ethics Advisory Committee is work out when we need to hear more from people outside of the Genomics England system, and I'm a great believer that if it's right that we need to go where people are, you have to try not to reinvent mechanisms to do that. You have to try and learn where are people already talking about it and go and listen to them there. Latha: Absolutely, yeah. I think they listen because I do work as a paediatrician with a safeguarding hat, and I think the same principles resonate in child death work. For example, simple messages about cot deaths, you would think that if a professional tells the same message to a parent or a carer it's better received if it's another family, a younger person, another layperson giving the same message. It comes back to who's more receptive. It could be a community worker. As you mentioned about vaccination, during the vaccination initiative I decided early on that I'm probably not going to do a lot because I'm not an intensivist, how do I do my bit in the pandemic. I decided to become a vaccinator and I thought with my ethnic minority hat on, if I went out there to the mass centres and actually vaccinated there or in mosques or wherever else, without even saying a word I'm giving the message, aren't I, that, look, I'm fearlessly coming and getting vaccinated and vaccinating others, so please come. I think that has helped to some extent, just trying to reach out. Other than saying these people are not reaching us, it's got to be the other way around.  [Break for advertisements]  Natalie: I'm really enjoying this conversation. In part because I think it highlights just how valuable it is to sort of think about ethics a little bit differently. Historically, and certainly I think within the research community, ethics can just be associated with consent. Consent is the ethics issue and if you solve for consent, then you don't have any other issues to think through. I think what this conversation is really highlighting is just how much broader the ethical considerations are. Beyond that, it's still very important that consent can be that sort of anchor point for communication and engagement, but it's not simply a one-off. And to be able to think through ethics not just in terms of risk or moving forward when things have gone wrong in the past, there is actually a really positive aspect to it which I think is critically important.   It's great to hear your thoughts about that different approach to ethics that I think does embed it much more in community thinking, in questions of equity; it's not just the individual. I want to follow-up by just asking where do you think the future lies in thinking about ethics both for Genomics England and the Ethics Advisory Committee, but in the space of genomic research and medicine more broadly, given that it sits in this kind of very interesting and quite complex space between research and care in the clinic.  Jonathan: I mentioned earlier in the conversation I think about this as a common enterprise that we have shared stakes in. Academic researchers have a stake in trying to build a better more robust evidence base, clinicians have a stake in being able to offer something to the people that they're looking after. Families have stakes not just in their own immediate care, but they worry about their siblings, they worry about their children, their grandchildren. There are also of course industrial players, so people trying to build a business out of making better medicines in the future. There are government players trying to use public resources more effectively. I think what we have to try to create is a mutual process where we recognise that everybody has overlapping but slightly different values that they're pursuing and trying to get out of it, and how can we make sure that we govern our work in a way that reflects all of those stakeholders and recognises the respect that's due to them. I think this is more like a sort of membership of a common project. And the problem with consent is it risks us saying you can be a member of this club but only if you accept the terms and conditions that the committee has decided is there. That's not going to be adequate going forward. I think we need to make sure that everybody feels that they are respected, that they feel they can place their trust in the system that we're designing. As an Ethics Advisory Committee, we have to ask ourselves what justifies us suggesting to people that this is trustworthy. We need to make sure we have good information governance that people are not going to expose themselves to breaches of privacy if they take part in this. But we also need to make sure that we don't waste people's efforts. If people are prepared to be part of the research project, we shouldn't have rules coming down on the data usage that say that we're going to reduce the value of that contribution by saying it can only be used for one project and can't be used for others, because actually that would not respect properly people's contribution to the process.   We need to ask ourselves not just about the protective element of trustworthiness but that element that says we will make sure that you get as much as we can design of the things that you think are important from this project. They won't be identical for each group, and they won't be identical within each group. Different family members of participants will have different balances, but they all have to believe that this is a good club to be part of and that they have been part of agreeing ways of working that they think will produce a better future that they want to be part of and that they want to be proud of saying we have helped create this future.  Latha: I kind of agree with all that you've said. I think it's most important not to forget because I'm also a participant, like my trio sample is there in the pipeline, and I know my data is sitting there. I also have trust that there is good information governance, the data is secure, so it's reinforcing that, but it's also being very honest that it's obviously the data is there, but we can't forget the person or the persons at the centre of it, so it's not just alphabets or sequences of alphabets, but it is that whole person, and that person represents a group of individuals, family members, different generations, and they have embarked on it. Even if they know they may not get hope they might provide hope for others. It's being therefore respectful. I think that is the first thing I think is the principle of it and if you respect. If you think it could be the same principle that we use in clinical practice, the friends and family test, because I've been on both sides of the consultation table, I think I've become a better doctor because I've been an anxious mum, and my anxieties were dismissed as being an anxious mum and I don't care. As far as my child is concerned, my anxiety was valid and so I would do everything to reach an outcome as to what's best for that person. It's made me a better doctor because I can see it from both the perspectives. Most of us are human beings, apart from AI technology looking at the dataset, so we all have conditions ourselves, we've got doctors with health conditions, we've got clinicians, academics, technicians, nurses everybody who's got a friend or a family member or themselves having a health condition. I think its fundamental principle is that friends and family test. How would I like my data stored? How would I like my data analysed? Could it do this, could it give me some information on how I would get cured or treated or be managed? How would it affect my insurance, or will it find out data about who's the father of this child, for example? It's being honest and being honest about the uncertainties as well.   When I'm recruiting, I'm very clear that these are what I know that I can tell you about the risks. But then there may be other risks that I do not know about. If you're honest about it and acknowledge what is the limit of the knowledge of science at this point in time, because you said there are so many stakeholders, there are researchers and academics who've got interest in some areas, it could have developed because of a family member having that problem, but whatever it is that is a great interest because that intelligent mind is thinking ahead and we need to encourage that. It could be for writing up papers, it doesn't matter. Whatever be the reason, if it's for the common good, that's fine. It's also thinking how are we keeping our families in the loop, so you have newborns, you've got young people sometimes with significant disabilities so they are relying on a parent or a carer to consent for them, but some are not so disabled but they have needs, they've got rare conditions, but they can make their consenting issues known when they turn 16, for example. It's the changing policies and they can withdraw at some point in life or there may be a member of the family who doesn't want to be part of that journey anymore. It's allowing that to happen. Jonathan: I think that's a really interesting example you've just touched on, Latha, where I may diverge a bit in terms of what I think is the key issue. The right to withdraw I think is a really interesting challenge for us going forward, because we developed the right to withdraw in the ethics of research studies that had physical interventions. It's really clear that someone who is being put to discomfort and is having things done to her body, if she wants to stop that, we can't justify continuing on the basis of it being a research project. But I'm less clear whether that applies to withdrawing data from data pools. I think there are a few dimensions to that which I hope as an Ethics Advisory Committee we'll have a chance to think through a bit more. One is the mutual obligations that we owe to each other. I'm not in these particular studies but I do try and take part in research studies when I'm eligible and invited to because I think research is important. When I take part in things and when our participants have taken part, they're doing something in which they rely on other people participating because the aggregation of the data is what makes it power. One of the things we have to be honest about is what are our mutual expectations of each other, so I think we absolutely have to hold on to the fact that people should be able to withdraw from further interventions, but I'm not convinced that you should have the right to say the data I've previously contributed that other people have relied on can suddenly be sucked out and taken out of it, because I think it's reasonable for us to say if this is a sort of part of an enterprise. While you're part of it, you've made some commitments as well as, and that's part of the mutuality of the respect. I think I personally would want to argue you can withdraw from new things, but provided that your privacy is not intruded on, so we're talking about data health anonymously, you shouldn't be able to say don't process it anymore. Latha: No, no, no. What I meant was from my perspective I would like to be constantly involved and get information through trickling. I don't know what my daughter feels years down the line, she might say I'm happy for my data to be used for research, but I don't want to know anymore. There are two aspects of that, and I think if we are clear with that and say continue with my data being used for research, but I don't want to get anymore letters. I think those are the kind of questions I face when I tell them families that these are the uncertainties, you can have your blood stored, you may not be approached again for a resampling unless you have some other issues, but are we happy with this? I think that's what I understand, and I try and recruit with that intention. Jonathan: And that makes lots of sense to me. As you say, you probably can't speak for your daughters now, and you certainly can't speak for them when they become parents for themselves and those things, but we do need to create an ethical framework which recognises that people will change their mind on things and people will vary about what they want to do. But because we have mutual obligations, what that means and the control we can give, we have to be open and honest about what choices we can give people without undermining the enterprise and what choices we say, “you don't have to do this, but if you want to be part of it, there are some common mutual obligations that are intrinsic”, and that's true of researchers, it's true of clinicians, it's true of anyone who works in Genomics England or the NHS.   But I don't think we've been very good at explaining to people that there's an element of this which is a package. A bit like when I bank, I allow the bank to track my transactions and to call me if they see something that looks out of the ordinary as a part of the protections from me. I can't opt out of that bit. I can opt out of them sending me letters and just say do it by email or whatever and I have some choices, but there's an infrastructure of the system which is helping it to function well and do the things it's able to do. I don't think we've been very good at explaining that to people, because we've tended to say, “as long as you've signed the consent form at the beginning of the process, it doesn't really matter what happens after that, you've been told.”. That's not enough I think for good ethics.  Latha: And I think that comes back to the other issue about training those who are consenting. I speak from personal experience within my own teams I can see somebody might say, “I don't do whole genomic sequencing consenting; I don't have the time for it.”. I might even have my organisational lead saying when we had a letter come through to say now we're no longer doing this, we're going to be doing this test for everybody, there's a whole gasp because it's at least two hours' worth of time and how are we going to generate that time with the best of intentions. I think that's where I think the vision and the pragmatic, you know, the grounding, those two should somehow link with each other. The vision of Genomics England with working with NHS England and with the future, Health Education England arm that is not amalgamated with NHS England, is trying to see how do we train our future clinicians who will hopefully consider it as part of their embedded working thinking and analysis, but also, how do we change the here and the now? The more senior conservative thinking people, who are worried about how do they have to generate time to manage, we're probably already a bit burnt out or burning out, how do they generate time? If you then discover new conditions whether there is already bottleneck in various pathways, how are we ethically managing the new diagnosis and how will they fit in in the waiting list criteria of those people on the journey who are symptomatic. I find that bottleneck when I have conversations with colleagues is the anxiety, how is that going to be addressed.  Jonathan: Latha, you've sort of taken us around in a circle. We started off thinking what was special about genomics, and we've reflected on ‘we have to solve the problems of the health service'. I think that there's some wisdom in that, because we are learning how to do things that are not unique to genomics, but there's an opportunity in genomics to do it better and an opportunity for us to help other areas of the health service do better, too. I think we've come around in full circle in a sense.  Natalie: Which feels like a lovely way to wrap up our conversation. I feel like we've gone into some of the deep ethical principles but also really shown how they can be brought into the practice, into the clinic and brought to bear the thinking and the feelings, the hopes the anxieties of participants. There's a very, very important range of different voices so a very rich discussion.   I'd just like to thank you both very much for joining us on the podcast. Thank you to our guests, Professor Sir Jonathan Montgomery and Dr Latha Chandramouli for joining me today as we discussed ethics in genomics research and practice. If you would like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app. Thank you for listening. I've been your host, Natalie Banner. This podcast was edited by Bill Griffin at Ventoux Digital, and produced by Naimah Callachand.

Pat Zigler with the CGH cardiac care unit talked about February, Heart Month and what's available for care at CGH.

Genetics is the transcript of your own personal health. We often perceive it as something that dictates that health issues are hereditary but the truth is that no one was born with chronic illnesses. In what way should we then perceive and interpret genetics?In this episode, Dr. Krista Kostroman is joined by Dr. Mansoor Mohammed, PhD. Dr. Mansoor is one of the founding members of The DNA Company as he had committed his life into studying genetics and all fields that revolve around it. He is a recognized authority in the fields of medical genomics and personalized medicine. He is the holder of several patents in the general fields of molecular diagnostics and genomics research. Dr. Mohammed completed his doctoral dissertation at the University of Guelph, Canada, majoring in both Molecular Immunology and Transgenic Technologies. He completed postdoctoral training in Clinical Cytogenetics at both UCLA and Baylor College of Medicine.Prior to becoming the scientific founder of The DNA Company, Dr. Mohammed co-founded Younique Genomics, served as the President and CEO of CombiMatrix Diagnostics—where he oversaw the development of one of the most comprehensive genomics testing menus in the diagnostic industry—and was the Director of Advanced Technologies at Quest Diagnostics, where he was honored with the Medical Innovation Award, the highest accolade given for excellence in medical research. Prior to his role at Quest Diagnostics, Dr. Mohammed was a founder and Director of Research and Development at Spectral Genomics. At Spectral Genomics, Dr. Mohammed pioneered the development of commercial Comparative Genomic Hybridization (CGH) array technologies and was responsible for the design and launch of the industry's first commercially available CGH arrays.Together, Dr. Krista and Dr. Mansoor go through the different stages and understandings of DNA that Dr. Mansoor went through - calling this the four epochs of his career.During the first epoch, Dr. Mansoor invented this whole genome technology where he studied human antibodies, and looked into animal models in order to deepen the study on the human's genetic makeup. This led him to founding companies such as Spectral Genomics and with the knowledge that they had at that time, they were able to focus on what was broken with the human body and used the study of DNA to find solutions to this. Moving on to 2011, he entered the second epoch of his career where he was questioned why they do not delve further than what was broken. This initiated Dr. Mansoor to dive deeper and study genomics with the addition of functional genomics. After continually studying what is unknown regarding a person's genomics, then comes the birth of The DNA Company. This story showcases how our clinicians today are able to prevent any possible illness by looking into a person's unique genetic makeup - even down to the body's smallest nuances.Onto the third epoch, the amount of information gathered must be handled with care so as not to dilute it in a soundbite that suggests that science is binary but rather give science its due right. This was when he realized that there was more to be done and stepped away to focus on studying yet continually serving people.Lastly, the fourth epoch dives into the study of hormone replacement and the continuous journey of advocating and researching for optimal human health, nutrition, lifestyle, and environment. ▬▬▬▬▬▬▬▬▬▬Keep yourself up to date on The DNA Talks Podcast! The DNA Talks Podcast Instagram https://www.instagram.com/dnatalkspodcast/Dr. Krista Kostroman's Official Instagram Page https://www.instagram.com/drkostromanofficial/This episode may also be viewed on YouTube

Olá, seja muito bem-vindo ao StandardsCast EP #225 ALL FLEET. Neste episódio conversamos com Lapenda e Roberta (Tripulantes Integrantes do Comitê de Escala) sobre as frentes de trabalho do Comitê de Escala da Azul. Falamos sobre o canal de comunicação via Forms para direcionar sugestões buscando melhorias na qualidade de vida dos tripulantes e as demandas que já foram atendidas pelo planejamento de escala por meio deste comitê, como as folgas agrupadas em dezembro, maior número de solicitações de folgas atendidas via PBS, base virtual, escala dirigida, folga nominata na data do aniversário dos filhos, e-mail informando o motivo da sigla REU com antecedência, divulgação da escala até o dia 20, férias casadas, e, por fim, o Forms com preferência de apresentação em GRU ou CGH para tripulantes da base Guarulhos. Link de acesso ao Forms para sugestões direcionadas ao Comitê de Escala: • https://forms.office.com/r/jM9tTXTv2Y Link de acesso ao StandardsCast #165 [ALL FLEET] Dicas de uso do PBS para a Escala de Tripulantes: • https://soundcloud.com/standardscast/xxx-all-fleet-dicas-de-uso-do-pbs-para-a-escala-de-tripulantes Em caso de dúvidas, críticas ou sugestões, envie um e-mail para standardscast@voeazul.com.br. Este Podcast foi produzido pela Diretoria de Operações da Azul Linhas Aéreas. Em caso de divergência entre qualquer assunto técnico abordado e os documentos oficiais, os documentos prevalecerão. Todos os direitos reservados.

Mary Jean Derreberry, CGH Director of Nursing Professional Development and Stephanie Waller, RN, CGH Digestive Health Services and DAISY Award Coordinator talk about the wonderful nurses at CGH during Nurses Week. To nominate your nurse (RN, LPN, Nurse Practitioner) for a Daisy Award, please go to cghmc.com/daisy to fill out an online nomination form.

Giveaway alert! Follow @musafirstoriespodcast on Instagram and check out our stories for a chance to win!   This week, The Musafir Stories speaks with Girin Nayak, the founder of XOtoXO games as he takes us on a trip to the Chettinad region!   Today's destination: Chettinad region, Tamil Nadu!   Nearest Airport: Madurai Airport, IXM   Nearest Railway Station: Chettinad Railway Station, CTDN   Prerequisites -  N/A   Packing - Pack light clothes and sunscreen if travelling in summers   Time of the year - December to Feb    Length of the itinerary: 3-4 days Itinerary Highlights:    Girin is the founder of XOtoXO games that brings stories from India to the world, one game at a time.  We cover the very popular but less explored region of Chettinad with Girin - Chettinad is a region in Tamil Nadu that covers over 90 villages and is the home of the prominent and enterprising Chettiyar community covering the Shivaganga and part of Pudukottai districts.  The Chettinad region is peppered with over a 11000 mansions built by the Chettiyar community between the mid 1800s to 1900s - these mansions were built by procuring materials from all over the world, thanks to the trading roots of the Chettiyar community who were seafaring merchants travelling all across Southeast Asia for trade.  We begin the journey in one of the main towns of the region - Kanadukathan, which serves as a good base, given its strategic location. Make sure to visit the popular mansions in the town - Chettinad Mansion, Vishalam by CGH group. Girin also describes the architectural features, and structure of these mansions along with the front yard, courtyard, rooms and kitchens along with open roofs. Other things to check out in Kanadukathan include the markets, temples and the abandoned airfield! The next stop on the itinerary is Karaikudi, one of the most developed towns in the region. The Aairam jannal veedu or 1000 window bungalow, The Bangala are two popular mansions in the region. There are also vibrant markets for textiles, souvenirs as well as antiques.  Another of the towns in the vicinity is Thirumayam - the popular attraction in the area is a fort known as Oomayan kottai or dumb man's fort, named after the brother of a famous Tamil freedom fighter who was executed here. The most famous mansion here is Chidambaram Vilas.  Athangudi is the next town on the itinerary and also happens to be the protagonist of today's episode, as it is also the source of inspiration for XOtoXO games' first board game. Athangudi not only has beautiful mansions but is also popular for its handmade tiles that are made in small factories. Girin also explains what goes into the making of the tiles and how this has inspired his first board game. We also talk about important temples in the region including one where terracotta horses are offered to the deity.  Finally we discuss one of the more popular exports of the region - the Chettinad cuisine!    Links: XOtoXO games on  Instagram: https://www.instagram.com/xotoxogames/ XOtoXO games on  Twitter: https://www.instagram.com/xotoxogames/ XOtoXO games on Facebook: https://www.facebook.com/profile.php?id=100077484262331 Link to website - https://www.xotoxo.com   Cover Photo by Nakkeeran Raveendran on Unsplash   Follow the Musafir stories on: Twitter : https://twitter.com/musafirstories?lang=en Facebook: https://www.facebook.com/themusafirstories/ Instagram: https://www.instagram.com/musafirstoriespodcast/?hl=en website: www.themusafirstories.com email: themusafirstories@gmail.com   You can check out IVM Podcasts website at https://shows.ivmpodcasts.com/featured Do follow IVM Podcasts on social media. We are @IVMPodcasts on Facebook, Twitter, & Instagram. https://twitter.com/IVMPodcasts https://www.instagram.com/ivmpodcasts/?hl=en https://www.facebook.com/ivmpodcasts/ Follow the show across platforms: Spotify, Google Podcasts, Apple Podcasts, JioSaavn, Gaana, Amazon Music Do share the word with your folks!See omnystudio.com/listener for privacy information.

This morning we heard from Danelle Saunders, Nurse Practitioner, in the CGH Cardiology department at the CGH Main Clinic. She was in to talk about CGH Cardiology and Heart Month (February) at CGH Medical Center. According to the CDC, February is American Heart Month, a time when all people can focus on their cardiovascular health. They are doing a campaign that encourages people to take small steps to address key risk factors like hypertension , high cholesterol , and  high blood sugar . To schedule an appointment with CGH Cardiology or for any of CGH heart services, please call (815) 625-4790. For more information on CGH Health Foundation Cholesterol and Glucose Screenings, please call Sherry at (815) 625-0400, ext. 5716

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.01.514641v1?rss=1 Authors: Du, Z., Shi, K., Brown, J. S., He, T., Wu, W.-S., Zhang, Y., Lee, H.-C., Zhang, D. Abstract: The formation of biomolecular condensates has emerged as a critical mechanism for compartmentation in living cells. Despite interactions between distinct condensates having been reported, the biological relevance of these interactions remains elusive. In germ cells, small RNA silencing factors are enriched in germ granule condensates, where distinct factors are organized into sub-compartments with specific functions linked to genome surveillance or transgenerational gene silencing. Here we showed that perinuclear germ granules are coated by P body condensates, which are known for housing translationally-inactive mRNAs and mRNA degradation factors. Disruption of P body factors, including CGH-1/DDX6 and CAR-1/LSM14, lead to dispersal of small RNA factors from perinuclear germ granules and disorganization of sub-compartments within germ granules. We further found that CAR-1 promotes the interaction between CGH-1 and germ granule factors, and these interactions are critical for the ability of CGH-1 to promote piRNA-mediated gene silencing. Importantly, we observed that cgh-1 mutants are competent in triggering gene silencing but exhibit defects in maintaining gene silencing in subsequent generations. Small RNA sequencing further showed that cgh-1 mutants exhibit defects in amplifying secondary small RNAs, known carriers of gene silencing memories. Together, our results uncover the function of P body factors in small RNA-mediated transgenerational gene silencing and highlight how the formation and function of one condensate can be regulated by an adjacent, interacting condensate in cells. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In this mini-series, we ask scholars at UCL to reflect on the meaning and practice of critical global health. Here, Professor Sahra Gibbon (UCL Anthropology) introduces us to the term "critical global health" (CGH), and explains some of the the key considerations involved in thinking about health critically. This podcast series is hosted by the UCL Grand Challenge of Global Heath, with support from the Faculty of Social and Historical Sciences and UCL Health, Mind and Society. For more information and to access the transcript: www.ucl.ac.uk/grand-challenges/disruptive-voices-critical-global-health-mini-series Date of episode recording: 2022-09-16 Duration: 00:03:00 Language of episode: English Presenter: Professor Sahra Gibbon Producer: Nina Quach

Tonight we talk about The Coast Guard House, a great New England restaurant and landmark. Elisa Wybraniec, Wine Director, talks with Mike and special Co-Host Gail Jencik, about the wine menu and the large variety CGH offers. We listen to music by jazz pianist Joe Parillo, who is the host of WCRI's Jazz After Dinner, to set the mood. For more information call (401) 789-0700, or go to www.TheCoastGuardHouse.com

CardioNerds Tommy Das (Program Director of the CardioNerds Academy and cardiology fellow at Cleveland Clinic), Rick Ferraro (cardiology fellow at the Johns Hopkins Hospital), and Dr. Aliza Hussain (cardiology fellow at Baylor College Medicine) take a deep dive on the REDUCE-IT trial with Dr. Peter Toth, director of preventive cardiology at the CGH medical center in Sterling, Illinois, clinical professor in family and community medicine at the University of Illinois School of Medicine, and past president of the National Lipid Association and the American Board of Clinical Lipidology.  Special introduction to CardioNerds Clinical Trialist Dr. Jeff Wang (Emory University). Audio editing by CardioNerds academy intern, Shivani Reddy. This episode is part of the CardioNerds Lipids Series which is a comprehensive series lead by co-chairs Dr. Rick Ferraro and Dr. Tommy Das and is developed in collaboration with the American Society For Preventive Cardiology (ASPC). Relevant disclosures: None Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Cardiovascular Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - REDUCE-IT The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) trial was a large randomized controlled trial that showed a significant reduction in atherosclerotic cardiovascular disease (ASCVD) events with use of icosapent ethyl ester in secondary prevention patients and high risk primary prevention patients with diabetes and residual elevated triglycerides between 135 to 499 mg/dL on top of maximally tolerated statin therapy1. Despite the use of high intensity statin therapy, considerable residual risk for future atherosclerotic cardiovascular disease exists in patients with ASCVD.Elevated triglycerides (TGs) are an important marker of increased residual ASCVD risk2.There are two primary types of Omega-3 fish oils: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omege-3 fish oils have been shown to lower triglyceride levels.Low-dose combination EPA and DHA has not exhibited incremental cardiovascular benefit in either primary prevention and secondary prevention patients on top of statin therapy3-5.REDUCE-IT showed the use of high dose EPA in patients with either ASCVD or DM and one additional risk factor, and relatively well-controlled LDL-C levels on maximally tolerated statin therapy and residual hypertriglyceridemia (TG 135-499 mg/dL) results in significant reductions in cardiovascular events over a median follow-up period of 4.9 years1. Show notes - REDUCE-IT Multiple epidemiologic and Mendelian randomization studies have established elevated triglyceride (TG) levels as an important risk factor for atherosclerotic cardiovascular events6-8. However previous clinical trials using TG-lowering medication such as niacin, fibrates and low dose omega-3 fish oil have not shown to reduce cardiovascular events when added to statin therapy in patients with or without ASCVD,9,10.The JELIS trial first demonstrated a significant reduction in cardiovascular events when 1.8g daily of eicosapentaenoic acid (EPA) was added to low-intensity statin therapy in patients with ASCVD and hypercholesterolemia, However, the trial was limited due to open label design without placebo, use of low doses of background statin therapy, and geographic/demographic limitations to participants in Japan11.In a large international multicenter randomized controlled trial, the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) randomized 8,179 patients with established atherosclerotic heart disease or diabetes and an additional risk factor, on maximally tolerated statin therapy, to 4 gm/day of icosapent ethyl (a highly purified and stable EPA ethyl ester) or miner...

A group of medical professionals arrived in Guyana this week to deliver care, exchange knowledge and develop a plan to support the more remote areas of the South American country. This work is part of a five-year medical partnership between the Ministry of Health of Guyana and Northwell Health, through its Center for Global Health (CGH). Daniel Leon is among those who traveled 2,500-plus miles for the three-week trip. He shares his experiences and connection to Guyana, as well as his passion for global health and the critical role the CGH plays. Also joining the show is Launette Woolforde, EdP, DNP, chief nursing officer for the Northwell's Western Region, who was part of the CGH's prior trip to Guyana in November 2021. Born and raised in Guyana, the chief nursing officer for Northwell Health's Western Region explains the benefits of clinicians broadening cross-cultural understanding, particularly for the communities of Little Guyana in Queens, as well as surrounding neighborhoods that makeup the fifth largest immigrant population in New York City. Donations to the Center for Global Health will benefit Northwell's Ukraine relief fund. Chapters: 01:08 - Daniel Leon on returning to Guyana 02:09 - EMS in a rough terrain 03:07 - Medical education in a tropical climate 03:57 - A deep connection 05:20 - Building a partnership 06:49 - A focus on mental health 07:39 - How to support global health efforts 08:56 - Launette Woolforde on nursing collaboration 10:45 - Mutual benefit 12:25 - Tropical medicine 13:46 - Local is global in Little Guyana 15:43 - Value for medical students 18:05 - A selfless cause Watch episodes of 20-Minute Health Talk on YouTube.   

Chicago beckons once again as we have a chat with Joe, lead singer of Capgun Heroes over the traditional medium of the telephone line. CGH are a relatively new band of older, wiser gentlemen who are really doing well just now. And nobody's more surprised than them, it seems!We talk terrifying experiences, backing vocal selection, picking your instrument of choice and one of the youngest Capgun Heroes fans makes an appearance!Tom has been out on the tiles, Niall's been slamming his opponents on the canvas and Brian (aka Grof) the dog has eyes bigger than his belly. The facts get political and we take our final look at Scottish punk offerings in North Of The Border Corner.Songs this week are from Shackleford, Before They Are Hanged, Grand Collapse, The Needles, The Filaments and Grudgepacker.

Nos acompañó Juan de Dios Hernández, abogado defensor de causas sociales, por mencionar algunas: la huelga del 99 y yo soy 132. Una historia conmovedora, importante y con mucho eco para seguir reflexionando.  Support the show: https://www.patreon.com/antifaz See omnystudio.com/listener for privacy information.

Hi friends, this is Dr. Michael Williams and welcome back to another episode of the diversify in path podcast. This podcast explores how investing in diversity can lead to a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of diverse voices within our field.My next guest is Dr. Dan MilnerDr. Milner completed his MD at the University of Alabama School of Medicine in 2000 and his residency/fellowship in Anatomic Pathology/Clinical Pathology/Microbiology at the Brigham and Women's Hospital in 2005. His masters of science in epidemiology is from the Harvard T. H. Chan School of Public Health were he remains an adjunct professor. He completed his masters in business administration from the UAB Collat School of Business. Dr. Milner began working in Africa in 1997 as a medical student and has built an international reputation as an expert in cerebral malaria. In parallel with this, he has been heavily involved in pathology capacity building in many countries and, most notably, led the team that built an anatomic pathology laboratory in Rwanda and Haiti for advance cancer diagnostics. Before joining ASCP in 2016, Dr. Milner spent 11 years at the Brigham and Women's Hospital/Harvard Medical School where he taught pathology, microbiology, and infectious disease; was the primary lead for infectious disease consultations in AP/CP; and was the recipient of numerous research grants in the areas of malaria and HIV. Dr. Milner is the author of over 150 publications and has presented national and internationally on his work in more than 25 countries. At ASCP, Dr. Milner is responsible for medical oversight of all organizational activities. He provides vision, direction, and execution of ASCP's Center for Global Health programs including communicable and non-communicable diseases. Dr. Milner and the CGH manage over 80 active collaborations with governments, NGOs, industry, academic centers, and international organizations with activity in more than 30 countries. Dr. Milner's leadership roles/experience with global efforts is extensive and he serves as a direct collaborative consultant in the area of diagnostic pathology for global health to Partners in Health, Mount Sinai, Memorial Sloan Kettering, Clinton Health Access Initiative, American Cancer Society, BIO Ventures for Global Health, Bristol-Myers Squibb, World Health Organization, World Economic Forum, World Child Cancer, Perkin-Elmer, International Collaboration for Cancer Reporting, International Cancer Control Partnership, City Cancer Challenge, and the Union for International Cancer Control.Twitter: @damilnermdInstagram: danmilnermdInstagram: ASCP_CMOPodcast: ‎Inside the Lab on Apple Podcasts This episode is also in memoriam to Dr. Felix M. BrownFelix M. Brown, M.D. '93, a pathologist and associate director of surgical pathology at Brigham and Women's Hospital, died of cancer on May 27 at his home in Dedham, Mass., at the age of 36. In his honor, the Department of Pathology at Harvard has created an annual award to be presented to pathologists-in-training whose qualities of humanity, generosity and dedication complement their talent as physicians.https://medicine.yale.edu/news/yale-medicine-magazine/in-memoriam-62080/

Today, Josh is covering the model of the Clinic Gym Hybrid. He gets a lot of questions about this in his inbox all the time, so he thought this episode giving an overview was more than past due. It's the start of the year, and Josh has already done 4 consultation calls with people looking to make the switch. On one hand it's great, but on the other, it makes him think it may have been a while since he explained exactly what the Clinic Gym Hybrid model is. “Clinical rehab, to me, is using your space with the tools of exercise… but you are using it in a clinical setting.” -Dr. Josh Satterlee Topics covered include: The purpose of today's episode. What are the 2 main parts of this model? About the clinic aspect. Transitioning to clinical rehab and what that means for you and your patients. The 80/50 rule and what it means. Why personal trainers aren't always the best coach hires. What can coaches do in your clinic to help both you and your patients? When to have patients see coaches versus seeing doctors. Insurance caveats and legislation in your state. How to build expertise in your coaches. Teaching red flags to your staff. Creating a successful signup method. The fitness/gym component of the CGH model. What is the fitness component and how does it relate to clinical rehab? The benefits of small group classes. Why your classes should be divergent. Selling and demonstrating expertise. Why you don't necessarily need lots of equipment. Find out more about Clinic Gym Connect: https://www.clinicgymconnect.com

Professors Alina Allen and Ian Rowe join the Surfers to discuss our ability to predict long-term outcomes using MR Elastography. The conversation flows around Mayo Clinic's recent Hepatology publication, "MRE for prediction of long term progression and outcome in chronic liver disease. The ability to predict long-term outcomes using MR Elastography (MRE) and other non-invasive testing methods will be pivotal to drug development and, separately, to diagnosing, staging and monitoring patients. Alina presents highlights from Mayo's recent CGH paper and lends her own significant experience in this area. As we learned last year, Ian leads or is involved in large population-based studies in Leeds, with considerable focus on how NITs can support patient treatment most successfully and cost effectively. This is a topic where all five panelists can contribute from unique perspectives reflecting their own experiences.Highlights include:8:53 - Alina Allen begins to discuss recent Mayo Clinic publication "MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease."10:22 - Source of data for this retrospective analysis11:33 - Discussion of results starts by discussing accuracy in pre-cirrhotic patients13:05 - Key point: biomarkers can tell us more because they are continuous numbers, not two or three level models14:08 - Stephen Harrison asks for specific numbers that listeners can use as rules of thumb for prediction15:08 - Alina -- a 1 point increase in kPa...more than doubles the risk of cirrhosis for pre-cirrhotic patients, increases risk of decompensation by 22% in compensated cirrhotics18:53 - Ian Rowe describes results as "great because it speaks to the development of more personal risk stratification for patients."19:53 - Alina expands on the benefit for clinicians who need to treat and manage individual patients more intelligently and cost effectively22:08 - Ian describes a study he and his team in Leeds are conducting that addresses similar issues. 24:09 - Alina raises question of how to monitor sub-F2 patients in hepatology and even primary care clinics24:59 - Louise Campbell: same metrics will allow us to individualize terminal care and palliation sooner for patients whose livers will fail. Leads to a more in-depth discussion with Ian on what should happen in the UK today vs. what is happening. 27:39 - Alina describes palliative care in the US as "an area that needs a lot more work" and raises some of the challenges30:13 - Stephen asks whether we can reverse engineer or analyze these results for FibroScan. Ian reports that his data suggests this is a more complicated challenge. 31:41 - Stephen asks about implications for endpoint designation in pre-approval outcomes studies, then suggests an alternate design with endpoints based on MRE33:10 - Alina agrees with idea, referring to Scott Friedman's point in S2 E51 about the genesis of NAFLD activity scores and fibrosis levels34:45 - Alina: "I think this connection between what we currently use to what we need to move in the future is starting to get made" and paints a picture for what trials might look like.36:15 - Stephen asks whether we know enough to propose a Subpart H endpoint that is not biopsy driven. He and Alina agree we are close to having one key endpoint proven: a 20% decreasae in MRE correlates to a 1 level decrease in fibrosis.

Michelle Hodge- Angelo's Pizza and CGH by Regional Media

Shari Jardine spent the last week in Ecuador vaccinating locals as part of Northwell's Center for Global Health (CGH) and joins the podcast from one of its vaccination pods. In March 2020, COVID-19 grounded Northwell's growing Global Health program, which had developed core sites in Guyana, India, and Ecuador. Eric Cioe-Pena, MD, CGH director, explains how the team maintained their global relationships virtually, and eventually resumed travel, starting with this three-week mission.  More from the experts Dr. Cioe-Pena explains how to develop an effective global public health program.

This week, former NFL Running back and ESPN Analyst Merril Hoge joined Ron to discuss how surviving open-heart surgery and Non-Hodgkin's Lymphoma had an impact on his health journey. Ron also sat down with Dr. Peter Toth, the Director of Preventive Cardiology at the CGH medical center in Sterling, Illinois. Their conversation focused around the importance of not just preventive care, but early preventive care when it comes to men and their heart health. They also discuss some of the early signs of heart disease, how to manage them and how to break the stigma of reaching out for care. To learn more: https://truetoyourheart.com00:00:00 - Intro00:01:49 - Interview with Dr. Peter Toth00:16:01 - Interview with Merril HogePresented by Amarin 

Sagi Haviv is a logo design legend. However, in this episode we go deeper and uncover what it takes to solve big brand & business problems. We discuss CGH's branding process using case studies from Discovery+, Harvard University Press and Chase Bank, as well as Sagi's biggest life lessons, how to “pressure test” a trademark & visual identity system, presentation techniques that win, when & how to break the rules, and ultimately how to “problem solve”. Hint… you first must define the business' problems & success criteria. Tune in for a monster value-packed episode.

Atenas Burrola joins the CGH to talk about her work at the Immigrant Justice Campaign working for and with immigrants and offering legal representation to ensure they receive fair and just treatment under the law. We also talk about nonprofits can think about their connection to the community they serve and how nonprofits can navigate advocacy work as a registered 501(c)3. We begin the episode discussing the importance of representation among five areas of your nonprofit: board of directors, staff leadership, front line staff, donors, and volunteers. Roger’s trivia question asks you to dig into the history of the iconic 80s band The Clash.

Dr. Rebecca Martin, Director of CDC's Center for Global Health (CGH), joins this episode to discuss their recently published Outbreaks Report and the important work CGH is doing around the world. She highlights several of the Center's programs, including the Field Epidemiology Training Program which has taught over 18,000 Disease Detectives to lead prevention, detection and response in more than 90 countries. Now the most experienced of those countries have begun to mentor others through crises.Dr. Martin goes on to talk about the impact of COVID-19 on the Center's programs, especially critical initiatives like measles and polio vaccination. She describes the Center's mission as “working globally to domestically.” The symbiotic nature of that mission has become increasingly apparent during this pandemic, as the lessons learned abroad are now helping to inform the response to COVID-19 at home.Takeaways:03:39 —The Center for Global Health's history, mission and 10-year anniversary successes.06:46 — Disease detectives: over 18,000 health professionals in 90 countries trained to lead prevention, detection and response.11:49 — How CGH programs have adapted and innovated in the face of COVID-19.18:15 — The impact of suspending programs due to COVID-19. The collateral damage from program suspension could have been greater than the virus itself.22:37 — What the next ten years holds for the Center for Global Health.24:51 — Three key examples of how investing in public health overseas has taught the U.S. valuable lessons that can be implemented at home.31:40 — Partnerships are key. This work cannot be completed alone.38:04 — Has the pandemic taught us to value equity?References:CDC - Global Health CDC 2021 Outbreak Report 

On the Vox Markets Podcast Today: 28th October 2020Vadim Alexandre, Head of Healthcare at SP Angel discusses covid testing stocks including Novacyt #NCYT and also Cambridge Cognition #COGJohn Meyer, Mining analyst and partner at SP Angel talks about: Altus Strategies #ALS Empire Metals #EEE Chaarat Gold #CGH & Kaz Minerals #KAZ(Interview starts at 14 minutes 46 seconds)Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.#VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcasthttps://www.voxmarkets.co.uk/

On the Vox Markets Podcast Today: 7th October 2020Vadim Alexandre, Head of Healthcare at SP Angel discusses Polarean Imaging's #POLX New Drug Application and request for priority review to the US Food and Drug AdministrationJohn Meyer, Mining analyst and partner at SP Angel talks about wind farms positive impact for resource companies and: Amur Minerals #AMC Chaarat Gold #CGH Solgold #SOLG Vast Resources #VAST Bushveld Minerals #BMN(Interview starts at 10 minutes 21 seconds)Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.#VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcasthttps://www.voxmarkets.co.uk/

On the Vox Markets Podcast Today: 5th August 2020 John Clarke, CEO of Gfinity #GFIN talks about the launch of their new digital motorsport competition V10 R-League, as part of Global Racing Series, which is a joint venture with Abu Dhabi Motorsport Management. John Meyer, Mining analyst and partner at SP Angel talks about, Beirut, China, Gold and mentions the following companies: Altus Strategies #ALS Anglo-Asian Mining #AAZ Bushveld Minerals #BMN Chaarat Gold #CGH Hummingbird Resources #HUM Kefi Minerals #KEFI IronRidge Resources #IRR Solgold #SOLG & Afritin #ATM (Interview starts at 21 minutes 41 seconds) Dr Tom McColm, Partner and Clean Tech Specialist at Baden Hill discusses: Ilika #IKA (Interview starts at 39 minutes 42 seconds) Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community. #VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcast https://www.voxmarkets.co.uk/

On the Vox Markets Podcast Today: 29th July 2020 John Meyer, Mining analyst and partner at SP Angel talks about: Altus Strategies #ALS Anglo Asian Mining #AAZ Bushveld Minerals #BMN Chaarat Gold #CGH Condor Gold #CNR Cora Gold #CORA Phoenix Copper #PXC Rio Tinto #RIO & Scotgold #SGZ Vadim Alexandre, Head of Healthcare at SP Angel discusses how testing for Covid-19 will become more prevalent and therefore be a big boost for related stocks such as: Avacta #AVCT Genedrive #GDR Novacyt #NCYT & Omega Diagnostics #ODX (Interview starts at 18 minutes 39 seconds) Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community. #VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcast https://www.voxmarkets.co.uk/

This week we review CGH school's closing performance of Heathers from March of 2020. It was a rough one! Behr gave it 5 stars which is really like a 1 or 2.We drop some facts about the musical and took a quiz which we did not do well on despite it supposedly being Beh'rs favorite.Of course, we found out which Heathers character we are and update you on all of the current Broadway news & happenings from around the world.

Dr. Paul Steinke, CGH by Regional Media

Experts estimate that headaches affect half the population, with up to 25% of headaches originating from the cervical spine or neck, which is referred to as a cervicogenic headache (CGH). There are many studies that demonstrate the effectiveness of chiropractic management for CGH, often involving a multi-modal treatment approach to address biomechanical dysfunction in the cervical spine that may contribute to or cause a patient's headache. These treatment options include… SPINAL MANIPULATION THERAPY (SMT): There are multiple methods or techniques of spinal manipulation to improve joint movement that can be sub-divided into two types: high velocity, low amplitude (thrust) where joint noise (called cavitation) occurs; and low velocity, low amplitude (non-thrust) where joint cavitation is not common. Some refer to the later as “mobilization.” Doctors of chiropractic often use both, but ultimately, the decision is decided by provider and patient preference. EXERCISE: On its own, exercise does not appear to be as effective as spinal manipulation, but when exercises—especially those targeting the deep flexors—are combined with SMT, the benefits last longer and are more satisfying in the long term. OCCIPITAL NERVE FLOSSING: Tension on the occipital nerve as it exits the skull can exacerbate CGH symptoms. Nerve flossing can reduce this tension. While lying on the back with the chin tucked in, the chiropractor lifts the patient's head and moves the chin toward the chest to stretch the muscular attachments at the base of the skull (which often pinch the nerves that cause headaches) while the patient bends the elbows to touch their collar bones. As the chiropractor lowers the patient's head, the patient extends their elbows and wrists/hands and lowers the arms toward the floor. This is frequently repeated five to ten times (depending on tolerance). ACTIVITY (ERGONOMIC) ADVICE: Here, your chiropractor assesses your work and hobbies, looking for ways to reduce the load on your neck and upper back. Forward head posture is VERY common and once identified, he or she can teach you ways to correct the faulty posture—often by making simple adjustments to the activity. HOME CERVICAL TRACTION: Traction works by stretching the vertebra and muscles. Though this can be done in the office, you can do it at home much more frequently. An over-the-door unit works well. Typical treatment time is 15 minutes. Gradually increase the weight to a maximum comfortable point (10-15 lbs. / 4.5-6.8 kg) is a common threshold of tolerance). The “KEY” is to RELAX to get the best effect. Bottomline: If you suffer from headaches, then it may benefit you to consult with a doctor of chiropractic to determine if your headaches may be caused or exacerbated by dysfunction in the neck. If so, then your chiropractor will have a variety of treatment options available to reduce the frequency and intensity of your headaches. www.PainReliefChiroOnline.com

Dr. Bill Bird from CGH by Regional Media

In this special episode, Debike Interviews Shilandren M, Vice President of CGH earth. Listen as they discuss travel in India as well as the history of CGH Earth and its beautiful luxury hotels

Cervicogenic headache (CGH) refers to headaches caused by dysfunction in the neck, and experts estimate that 18% of chronic headache patients have cervicogenic headaches. Spinal manipulative therapy (SMT) is a form of treatment most commonly provided by doctors of chiropractic, and several studies have demonstrated that SMT is highly effective for patients suffering musculoskeletal disorders of the neck, including those with cervicogenic headaches. However, there remains little consensus on the appropriate number of SMT treatments to achieve maximum benefits for CGH. In a 2018 study, a team of researchers conducted a large-scale study involving 256 chronic CGH patients to determine how many treatments are needed to achieve optimum results using SMT for CGH. The investigators randomly assigned participants to one of four dose levels (0, 6, 12, or 18 visits) of SMT for six weeks. The type of SMT consisted of a manual high-velocity, low-amplitude (HVLA) thrust manipulation in the cervical and upper thoracic regions. The location of the spinal adjustment was determined by a brief, standard spinal palpatory examination from the occiput to T3 to assess for pain and restricted motion. For older patients and/or those in acute pain, the manual therapy was modified to a low-velocity, low-amplitude mobilization. To control for visit consistency and provider attention, patients continued to receive a light massage treatment once a patient's assigned number of visits was satisfied, until the six-week treatment period ended. After the conclusion of the treatment phase of the study, the participants used a headache diary to keep track of their headaches for the next year. The results showed that the patients who received the most SMT treatments had fewer headaches over the following twelve months. More specifically, the researchers calculated that six additional SMT visits resulted in about twelve fewer days with headaches over the next year. If you suffer from headaches, consider consulting with a doctor of chiropractic to determine if cervical dysfunction is a potential cause or contributing factor and whether you are a candidate for spinal manipulative therapy. www.PainReliefChiroOnline.com

Chris Runde is the Senior Director of Strategic Development at CGH Technologies. CGH is an aviation innovation firm providing management consulting and solutions to public and private customers. Prior to his current role, Chris held numerous executive, aviation-related positions in the public and private sectors. He’s lead initiatives in airport biometric credentialing, the first deployment of TSA PreCheck as a core member of the Risk-based Security team, and worked on a venture-backed startup. In this episode, you’ll hear Ken and Chris discuss where innovation & autonomy will impact airport, trends in UAS applications, and how to go about innovating in a slow-moving industry. Connect with Chris https://www.linkedin.com/in/christopherrunde/ Find every episode’s show notes at Catalyst-go.com

What’s up? No podcast de hoje, falo sobre reservar um voo. Enjoy :-) Transcrição Hi, everyone, how's it going? Is it boiling in Brazil yet? Here in my neck of the woods it's getting colder and wetter every day. Sorry, I didn't mean to brag... Anyway, I thought that having a look at one of these booking websites where you can search and find your flight would be a good idea. There's some interesting vocabulary involved - let's dive right into it. The website I'm looking at has kind of a funny name: Momondo. I'm looking at it right now and... What does it look like? At the top you have sort of search form where you enter the airport you're departing from. And then you enter the other airport where your flight is supposed to arrive. You enter first the three-letter code for the departure airport - let's say you're departing from... if it's an international flight, maybe you're departing from Guarulhos, which is GRU. Or if you want to go somewhere, I don't know, in Brazil and you're departing from São Paulo, you're going to enter CGH which is the three-letter code for Congonhas, then you enter the dates. The date (when) you're going to depart, and then if it's a round trip you're going to enter your return date as well... Or maybe you're just looking at a one-way ticket and then you only enter one date, which is the departure date. Then you hit Search and when you look at the results you, obviously see a list of flights. Several options from several different airlines, and you'll be able to see the dates - usually it will be the dates that you entered. You'll be able to see, for each flight, how many stops, how long each stop takes... The time of the flight, and then you have some options: either you'll see a few direct flights, which are usually more expensive, and you will see some flights with one, or two, or sometimes even three stops. There are some flights that - with all the stops - take, sometimes, over 24 hours. If you want to save some money maybe that's the flight you choose. And then, when I scroll down on the search results, I see multiple different airlines. I see some traditional ones like TAP, which is a Portuguese one, KLM, which is a Dutch one, British Airways... And then on the left side of the search results there's the sidebar with additional options. Right on the top you have... almost at the top, you have the option of, I guess, narrowing down your search by number of cabin bags, or checked bags that you want to take, and also the payment method. What is a cabin bag? That's... that's also known as a carry-on bag. That's sort of, that smaller bag - when you board the plane you take it with you, and you sort of put it in the overhead compartment above your seat. Or, if that is full, you kind of tuck it away under the seat in front of you. Usually the flight attendants will help you with that. That's the cabin bag or carry-on bag. And then you also usually have a checked bag, depending on... if it's a budget flight, sometimes you have to pay quite a bit of money to be able to take a checked bag with you, and for other flights, longer flights... It's included in the price. You can take a checked bag with you, which is actually that larger bag. It's that large suitcase where you put all your clothes. If you're traveling for a month, you'll probably need a large suitcase. You stuff all your clothes in there, and your toiletries, and your shoes and whatever else you want to take with you. That's the larger bag and obviously you can't board the plane with that bag. You have to get to the airport with some time in advance and check that bag. And then scrolling down a bit further, I find that there are some options for "flight quality": you can choose "show Wi-Fi flights only", "show flights with multiple tickets for booking", "show red-eyes". This is an interesting expression. A red-eye flight is any flight departing late at night and arriving early the next morning.

Show Notes for Oct 2019 – Episode 35 Appropriate therapeutic drug monitoring of Biologic agents for Patients with IBD – CGH The View from Europe – TDM  – CGH  Cold snare vs Heparin bridging and hot snare polypectomy in patients on anticoagulants with subcentimeter polyps. – Annals of int Med. High-Dose Vitamin D Supplementation on… Continue reading GI Pearls – October 2019 – Episode 35 Gastroenterology Literature Review

En noviembre de 1999 el movimiento tumba a Barnés y el gobierno impone a Juan Ramón de la Fuente en la rectoría; éste y gobernación tienen un plan bajo la manga: aislar al CGH fortaleciendo al ala del movimiento que se opone al diálogo público (la autonombrada megaultra), aislando al ala que plantea usar el diálogo público como tribuna para difundir las demandas de la huelga, y ganar a la población derrotando ideológicamente la embestida del gobierno para expulsar a todo un sector social de la universidad. Integrantes de este ala son calumniados y difamados con primeras planas en periódicos. El plan les resulta momentáneamente: el CGH llega amordazado al diálogo, impedido a argumentar el pliego petitorio; las autoridades usan el diálogo público para aislar a los huelguistas. El golpe surte efecto varias semanas, pero en enero del 2000, la huelga se va revitalizando y las calumnias quedando rebasadas. Su nuevo plan fracasa. #CGHa20Años

En 1986-87, la dirigencia del CEU pactó el fin de la huelga con las autoridades, sin consultar a las asambleas. Esto marcó todo el movimiento estudiantil del CGH, había vigilancia de masas, control de los representantes por las asambleas, cuestiones democráticas fundamentales, pero también una gran desconfianza que las autoridades supieron utilizar hacia el final de la huelga. #ConversandoSobreLaHuelga #CGHa20Años

Entrevista de Radio Educación a Ex miembros del CGH de 1999. Viernes 23 de agosto de 2019. Hablan: Rosa María Bayona, Vinicio Gómez e Ivalú Cacho.

Physical therapists Geoff Wright and Nolan Wolfe discuss the expanded CGH physical therapy, occupational therapy, speech therapy and pediatric rehabilitation therapy programs.

Physical therapists Geoff Wright and Nolan Wolfe discuss the expanded CGH physical therapy, occupational therapy, speech therapy and pediatric rehabilitation therapy programs.

Dr. Scott Reese discusses CGH's interventional cardiology services and its recent Chest Pain Center certification.

Dr. Scott Reese discusses CGH's interventional cardiology services and its recent Chest Pain Center certification.

Live Paranormal Sunday Aaron Sagers, Dustin Pari, CGH